Angiosarcomas of Primary Gynecologic Origin A Clinicopathologic Review and Quantitative Analysis of Survival

被引:29
作者
Kruse, Arnold-Jan [1 ,2 ]
Sep, Simone [3 ,4 ]
Slangen, Brigitte F. M. [1 ,2 ]
Vandevijver, Nathalie M. [6 ]
Van Gorp, Toon [1 ,2 ]
Kruitwagen, Roy F. [1 ,2 ]
Van de Vijver, Koen K. [1 ,5 ]
机构
[1] Maastricht Univ Med Ctr, Sch Oncol & Dev Biol, GROW, Maastricht, Netherlands
[2] Maastricht Univ Med Ctr, Dept Obstet & Gynecol, Maastricht, Netherlands
[3] Maastricht Univ Med Ctr, Dept Internal Med, Maastricht, Netherlands
[4] Maastricht Univ Med Ctr, Dept Epidemiol, Maastricht, Netherlands
[5] Maastricht Univ Med Ctr, Dept Pathol, Maastricht, Netherlands
[6] Atrium Med Ctr Parkstad, Dept Pathol, Heerlen, Netherlands
关键词
Angiosarcomas; Female genital tract; Treatment; Review; Prognostic factors; PRIMARY UTERINE ANGIOSARCOMA; MATURE CYSTIC TERATOMA; EPITHELIOID ANGIOSARCOMA; THE-LITERATURE; UTERUS; OVARY;
D O I
10.1097/IGC.0000000000000020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective Angiosarcomas are aggressive, malignant soft tissue neoplasms of endothelial origin and occur rarely in the female genital tract. There is lack of consensus on risk factors for poor outcome and optimal treatment. To this end, we performed a clinicopathologic review and survival analysis. Methods We report a case of a woman with an angiosarcoma of the vagina. Published English literature was reviewed for angiosarcomas of the vulva, vagina, uterus, and ovary. Survival was evaluated by using Kaplan-Meier analysis and the effect of clinical and demographic variables on survival by using Cox regression analysis. Results A total of 51 patients were identified with a median age of 47 years (range, 17-87 years). Two of the patients had an angiosarcoma of the vulva; 2 had an angiosarcoma of the vagina; 18 had an angiosarcoma of the uterus, and 29 had an angiosarcoma of the ovary. Five-year overall survival was 27% (SE, 8%). Most patients presented with locoregional disease, having surgery as their primary intervention. Overall, adjuvant therapy significantly improved survival (hazards ratio, 0.17; 95% confidence interval, 0.05-0.59; adjusted for age and tumor size). Adjuvant treatment consisted of radiotherapy for angiosarcomas of the vulva, vagina, and uterus and chemotherapy for ovarian angiosarcomas. Subgroup analysis of the female genital tract site was hampered by the small number of cases. Conclusions This review supports the use of surgical and adjuvant radiotherapy for angiosarcomas of the vulva, vagina, and uterus. Cytoreductive surgery and adjuvant chemotherapy remain the primary treatment of angiosarcomas of the ovary.
引用
收藏
页码:4 / 12
页数:9
相关论文
共 31 条
[1]  
[Anonymous], 2008, ENZINGER WEISSS SOFT
[2]   Primary angiosarcoma of the ovary complicated by hemoperitoneum: a case report and review of the literature [J].
Bradford, Leslie ;
Swartz, Kathryn ;
Rose, Stephen .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2010, 281 (01) :145-150
[3]  
Cambruzzi E., 2010, PATHOLOG RES INT, V2010
[4]   Angiosarcoma of the uterus: Report of 2 new cases with deviant clinicopathologic features and review of the literature [J].
Cardinale, Loredana ;
Mirra, Maurizio ;
Galli, Carlo ;
Goldblum, John R. ;
Pizzolitto, Stefano ;
Falconieri, Giovanni .
ANNALS OF DIAGNOSTIC PATHOLOGY, 2008, 12 (03) :217-221
[5]   Angiosarcoma Arising in Mature Cystic Teratoma of the Ovary: A Case Report and Review of the Literature [J].
Contreras, Alejandro Luina ;
Malpica, Anais .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2009, 28 (05) :453-457
[6]   Primary ovarian angiosarcoma presenting as malignant cells in ascites: Case report and review of the literature [J].
Davidson, B ;
Abeler, VM .
DIAGNOSTIC CYTOPATHOLOGY, 2005, 32 (05) :307-309
[7]  
DAVOS I, 1976, Gynecologic Oncology, V4, P70, DOI 10.1016/0090-8258(76)90009-3
[8]  
den Bakker MA, 2006, J CLIN PATHOL, V59, P658, DOI 10.1136/jcp.2005.029751
[9]  
DRACHENBERG CB, 1994, AM J CLIN PATHOL, V102, P388
[10]   MALIGNANT HEMANGIOENDOTHELIOMA OF THE UTERUS [J].
EHRMANN, RL ;
GRIFFITHS, CT .
GYNECOLOGIC ONCOLOGY, 1979, 8 (03) :376-383